Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Trends in Oncology from ACCC Annual Report Reveal ‘Silver Lining’ of the Pandemic

May 26, 2021
By Audrey Sternberg
Article

The 2020 Trending Now in Cancer report highlighted a shift in oncology care resulting from the COVID-19 pandemic.

Results from the Association of Community Cancer Centers’ (ACCC) annual report, Trending Now in Cancer Care 2020, reveal the extent of the COVID-19 pandemic on cancer care and oncology professionals.

Straying from the organization’s typical structure of conducting surveys for the report, the team at ACCC conducted focus groups in 2020 to better understand the experiences of health care providers. This decision was made due to the high demands on multidisciplinary care providers over the previous year. Topics discussed included staffing and operational integrity, service line delivery and revenue optimization, telehealth and supportive technology, clinical research, and health equity.

“This report is critically important and unlike any other, in that we are able to identify the impact of the pandemic on cancer programs and their staff, and tailor our resources to incorporate the lessons learned over the past year,” Krista Nelson, MSW, LCSW, OSW-C, FAOSW, who is ACCC President and Program Manager of Quality and Research, Cancer Support Services & Compassion for the Providence Cancer Institute in Portland, Oregon, said in a press release. “Feedback from members reaffirmed ACCC’s commitment to focus on education and resources to promote equity, diversity, and inclusion within oncology, and build a culture of resilience for cancer care staff.”

As expected, findings of the survey showed that COVID-19 weighed heavily on providers in the oncology space. Factors contributing to the added stress ranged widely and included financial hardships from layoffs, exhaustion from burnout, and the emotional toll of social distancing measures. Managers and leaders reported that the added burden of caring for the needs of their staff was a “full-time occupation”.

In line with available research indicating that the pandemic led to a drop in cancer screenings, the focus groups confirmed that their experiences matched the findings of investigators. Adding to that, many reported that necessary screening measures have not resumed to pre-pandemic levels. As such, participants surmised that more advanced cancers at diagnosis are likely to be recorded in 2021 and beyond.

Reduced or suspended services and the overall reduction in patient volume adversely impacted revenue to the health care system. However, since oncologic services such as chemotherapy infusions and radiation treatments remained steady during the early months of the pandemic, cancer programs served to financially “shore up” the health care institutions whose other service lines diminished care.

A more robust telehealth structure emerged as a welcomed side effect of the pandemic, accounting for between 40% to 50% of patient volume in 2020. However, greater reliance on these methods of communication has created a “digital divide” where certain patients, especially those in rural areas where cell phone service and connectivity are lacking, do not have equal access.

Exacerbated by the presence of the virus, health disparities in general and those specific to oncology came to the forefront. Socioeconomic, racial and ethnic, age, gender and geographic divides are served to aggravate health outcomes, which in turn motivated cancer programs across the country to act. New efforts like extending office hours, assisting patients with transportation, and partnering with community organizations were implemented to assist those who had difficulty accessing needed care. In addition, ACCC reported that added flexibilities in clinical research have the potential to positively impact the conduct of clinical trials in the long term, which may result in untold benefits to providers and their patients.

Ultimately, the findings revealed “silver linings” to come from the disruptions of the pandemic, with focus group participants reporting “how their cancer programs and practices developed new operational approaches and workflows to minimize disruptions to staff and patients and ensure continuity of care.”

References

1. Trending now in cancer care. Association of Community Cancer Centers. May 2020. Accessed May 26, 2021. https://bit.ly/3hSG2XF

2. Association of Community Cancer Centers Releases Report: Trending Now in Cancer Care 2020. News release. Association of Community Cancer Centers. May 24, 2021. Accessed May 26, 2021. https://bit.ly/3hUpuyh

Recent Videos
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Hydration and a healthy, well-balanced diet may mitigate fatigue among patients undergoing treatment for cancer.
Bland foods, such as crackers and chicken noodle soup, as well as fluids with electrolytes, may help stave off treatment-related nausea.
According to Denise B. Reynolds, RD, patients eating well should not be experiencing nutritional deficiencies during cancer treatment.
Related Content
Advertisement

Black patients experienced lower survival rates across cancer types and several categories of urbanicity, particularly in breast and colorectal cancers.

Five-Year Cancer Survival Rates Lower Among Rural Cancer Populations

Roman Fabbricatore
September 25th 2025
Article

Black patients experienced lower survival rates across cancer types and several categories of urbanicity, particularly in breast and colorectal cancers.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


Greater regulatory and policy clarity may better optimize clinician use of artificial intelligence in treating patients with cancer.

Advancing AI in Oncology: Critical Considerations for Clinical Practice

Roman Fabbricatore
September 19th 2025
Article

Greater regulatory and policy clarity may better optimize clinician use of artificial intelligence in treating patients with cancer.


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


Clinical benefit with the investigational agent was reported among 48% of patients with solid tumors at or above the therapeutic dose threshold.

LP-184 Shows Favorable Safety, Pharmacokinetics in Advanced Solid Tumors

Roman Fabbricatore
September 17th 2025
Article

Clinical benefit with the investigational agent was reported among 48% of patients with solid tumors at or above the therapeutic dose threshold.


Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Tim Cortese
September 10th 2025
Article

Rezatapopt achieved an ORR of 33% in all patients, and an ORR of 43% in patients with ovarian cancer, with 1 confirmed complete response.

Related Content
Advertisement

Black patients experienced lower survival rates across cancer types and several categories of urbanicity, particularly in breast and colorectal cancers.

Five-Year Cancer Survival Rates Lower Among Rural Cancer Populations

Roman Fabbricatore
September 25th 2025
Article

Black patients experienced lower survival rates across cancer types and several categories of urbanicity, particularly in breast and colorectal cancers.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


Greater regulatory and policy clarity may better optimize clinician use of artificial intelligence in treating patients with cancer.

Advancing AI in Oncology: Critical Considerations for Clinical Practice

Roman Fabbricatore
September 19th 2025
Article

Greater regulatory and policy clarity may better optimize clinician use of artificial intelligence in treating patients with cancer.


How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.


Clinical benefit with the investigational agent was reported among 48% of patients with solid tumors at or above the therapeutic dose threshold.

LP-184 Shows Favorable Safety, Pharmacokinetics in Advanced Solid Tumors

Roman Fabbricatore
September 17th 2025
Article

Clinical benefit with the investigational agent was reported among 48% of patients with solid tumors at or above the therapeutic dose threshold.


Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Tim Cortese
September 10th 2025
Article

Rezatapopt achieved an ORR of 33% in all patients, and an ORR of 43% in patients with ovarian cancer, with 1 confirmed complete response.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.